"Thorough Investigation Into Placebo Group Results"
Will Reflect Findings in Future Steps, Including US FDA Approval

Seungho Jeon, Co-CEO of Kolon TissueGene, described the results of the US Phase 3 clinical trial for the cell and gene therapy for osteoarthritis, TG-C, as "a half-success rather than a failure." He explained that while the treatment group achieved efficacy similar to or higher than previous trials, the placebo group showed an unexpectedly large improvement in pain relief, resulting in the trial not demonstrating statistical significance.


At a press conference held on July 21, 2026, at the Kolon One & Only Tower in Gangseo-gu, Seoul, Co-CEO Jeon stated, "The clinical results of the TG-C administration group were equal to or exceeded the effects seen in the Korean Phase 3 and US Phase 2 trials," adding, "Through several months of analysis, we will investigate the reasons behind the unusually high placebo effect."


Seungho Jeon, CEO of Kolon TissueGene, is explaining the topline results of the TG-C Phase 3 clinical trial in the United States at a press conference held on the 21st at the Kolon One&Only Tower in Gangseo-gu, Seoul. Photo by Seongmin Lee

Seungho Jeon, CEO of Kolon TissueGene, is explaining the topline results of the TG-C Phase 3 clinical trial in the United States at a press conference held on the 21st at the Kolon One&Only Tower in Gangseo-gu, Seoul. Photo by Seongmin Lee

View original image

According to the top-line results of the US Phase 3 clinical trial recently announced by Kolon TissueGene, TG-C did not achieve statistical significance over placebo in either of the primary endpoints: the Visual Analogue Scale (VAS) for pain and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). In both endpoints, the placebo group showed pain reduction at a level similar to the TG-C administration group.


The company believes that the larger-than-expected placebo response at the time of the trial design significantly affected the outcome. Rather than the TG-C group underperforming, it argues that the abnormal degree of improvement in the placebo group minimized the difference between the groups.


Moonjong Roh, Co-CEO of Kolon TissueGene, commented, "In osteoarthritis clinical trials, it's typical for the placebo group's VAS and WOMAC scores to decrease by about 9 to 14 points, with these effects lasting up to six months before gradually diminishing. In this trial, both endpoints displayed truly atypical results."


He added, "We need to conduct subgroup analyses by patient cohort to pinpoint the cause, and at this stage, it is difficult to definitively identify which factors were problematic."



Kolon TissueGene plans to review the raw patient data and analyze the reasons behind the high placebo response. The company will comprehensively examine factors such as patient characteristics, differences between clinical centers, and the assessment process, and will reflect these insights into its future US Food and Drug Administration (FDA) approval strategy and subsequent procedures. Co-CEO Jeon said, "We will identify the underlying causes through detailed raw data analysis and prepare additional measures and responses for FDA approval."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing